MyoPax

The vanguard in cell and gene therapies for muscle disorders

MyoPax is developing a method for the isolation and cultivation of regenerative muscle stem cells.

This enables MyoPax to produce large high-purity populations of stem cells that they call PHSats: Primary Human Satellite cell derived muscle stem cells.

MyoPax is based in Berlin, Germany/Copenhagen, Denmark and is headed by the CEO and Co-founder Verena Schöwel-Wolf.

MyoPax joined NOME in 2022.

Company details

Website

Myopax.com

More companies

Adamant HealthNOME2024-07-09T12:33:39+00:00

Adamant Health
Adamant Health

Medical Devices
Alder TherapeuticsNOME2024-07-09T12:27:31+00:00

Alder Therapeutics
Alder Therapeutics

Therapeutics
CSW TherapeuticsNOME2024-07-09T12:20:00+00:00

CSW Therapeutics
CSW Therapeutics

Medical Devices
Inform LifeNOME2024-07-09T12:35:35+00:00

Inform Life
Inform Life

Other
Reccan DiagnosticsNOME2024-07-09T12:03:38+00:00

Reccan Diagnostics
Reccan Diagnostics

Diagnostics
Fuse VectorsNOME2024-07-09T11:39:06+00:00

Fuse Vectors
Fuse Vectors

Therapeutics
MetsystemNOME2024-05-30T11:11:02+00:00

Metsystem
Metsystem

Digital Health
Droplet IVNOME2024-04-15T08:52:38+00:00

Droplet IV
Droplet IV

Medical Devices

VIEW ALL PROJECTS

MyoPax

Project Description

MyoPax

Company details

Website

More companies